Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Completed No phase listed Observational

Collections of Blood and Stool Samples in Patients With Acute Hepatitis

NCT00001879
View directory record Official record
Conditions
Hepatitis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01667731
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

NCT01311674
View directory record Official record
Conditions
Healthy Volunteers
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
20 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Altamonte Springs, Florida • Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 21, 2026, 10:34 PM EDT
Completed No phase listed Observational

Study of Transfusion-Transmitted Infections

NCT00023023
View directory record Official record
Conditions
Viral Disease, Blood Donation, Transfusion-Transmitted Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
1,771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Not applicable Interventional

A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C

NCT01250743
View directory record Official record
Conditions
Hepatitis C
Interventions
ascorbic acid (vitamin C)
Dietary Supplement
Lead sponsor
Health Innovations, Frontier Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2011 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Testing of a Navigation Intervention for Hepatitis C and HIV

NCT04499651
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Hepatitis C
Interventions
Navigation
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

NCT02175966
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir, Peginterferon α-2a
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Rialto, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 21, 2026, 10:34 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

NCT01890772
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Peginterferon alfa-2a, Ribavirin, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
Long Beach, California • Minneapolis, Minnesota • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Study of VX-985 in Subjects With Chronic Hepatitis C

NCT01144936
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
VX-985 or matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Overland Park, Kansas • Baltimore, Maryland • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment

NCT04971928
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

NCT00128271
View directory record Official record
Conditions
Hepatitis C
Interventions
Bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

NCT01943799
View directory record Official record
Conditions
Chronic HBV Infection
Interventions
GS-4774, OAV Regimen
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

NCT01153919
View directory record Official record
Conditions
Hepatitis C Infection, Thrombocytopenia
Interventions
romiplostim, ribavirin, placebo, PEG-interferon alfa-2a, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Study of SCY-635, Pegasys and Copegus in Hepatitis C

NCT01265511
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Placebo, SCY-635, Pegasys, Copegus
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Francisco, California • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

Ph IIA Study (SOC +/- NS5B)

NCT01193361
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

NCT00097435
View directory record Official record
Conditions
Hepatitis C
Interventions
Albuferon, Ribavirin
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 4 Interventional

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

NCT00141284
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Bakersfield, California • Miami, Florida • Shreveport, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

NCT01559844
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Sofosbuvir, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 4 Interventional

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

NCT00722332
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepaGam B
Biological
Lead sponsor
Cangene Corporation
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy

NCT01912404
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
IDN-6556, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Indianapolis, Indiana • Rochester, Minnesota • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 4 Interventional Results available

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

NCT01327547
View directory record Official record
Conditions
HIV Coinfection
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Bakersfield, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

NCT01856426
View directory record Official record
Conditions
Hepatitis C
Interventions
EDP239, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 21, 2026, 10:34 PM EDT